Download by
Scanning QR Code
No Stock Yet
China Shineway Upgraded to Buy From Hold at Jefferies
Hong Kong stocks of traditional Chinese medicine continued to rise, Shenwei Pharmaceutical rose nearly 17%
Interim dividend 39 cents per share Shenwei Pharmaceutical's interim net profit increased by 21.6% to 308 million yuan compared with the same period last year.
Shenwei Pharmaceutical (02877) released its results for the six months ended June 30, 2021. The group made a profit of 1.554 billion yuan (the same unit below), an increase of 30.58% over the same period last year; a profit of 308 million yuan, an increase of 21.57% over the same period last year; and basic earnings per share of 41 points. The increase in net profit was lower than that of sales and the decline in net profit margin was mainly due to a total decrease of 42.2% in investment income and other income in the first half of this year compared with the same period last year. The operating profit before tax in the first six months of 2021, excluding investment income, other income, financial costs and taxes, was 2.98.
Shenwei Pharmaceutical (02877.HK) held a board meeting on August 31st to approve the interim results.
Original title: Shenwei Pharmaceutical (02877.HK) held Board meeting on August 31 to approve interim results Source: Gelonghui August 19, Shenwei Pharmaceutical (02877.HK) announced that the board of directors will hold a board meeting on August 31, 2021 to, among other things, approve the release of the company's interim results for the six months ended June 30, 2021 and consider the declaration of an interim dividend.
Morgan Stanley: maintain Shenwei Pharmaceutical (02877) "hold" rating target price increased by 13% to HK $7.80
Original title: big Motors: maintain Shenwei Pharmaceutical (02877) "hold" rating Target Price increased by 13% to HK $7.80 Source: Zhitong Financial APP has learned that JPMorgan has released a research report that the new dividend plan based on Shenwei Pharmaceutical (02877) actually guarantees 15% annual profit growth in the next few years, and raises its profit forecast for 2021-25 by 10% to 13%, which is expected to be mainly driven by an increase in sales. Forecast for an increase in the dividend payout ratio. Morgan Stanley updated its risk return to the company, raising its target price by 13% from HK $6.9 to HK $7.8, maintaining its "hold" rating.
Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) soared by more than 7% in the afternoon and adopted the new dividend policy four times a year since 2022.
Original title: Hong Kong stocks change | Shenwei Pharmaceutical (02877) soared more than 7% in the afternoon to adopt a new dividend policy four times a year since calendar year 2022: Zitong Financial APP has learned that Shenwei Pharmaceutical (02877) announced that the company expects to declare and distribute a total dividend of 60 cents per share in calendar year 2021. In addition, the Board has approved and adopted a new dividend policy with effect from July 19, 2021. The stock surged more than 7 per cent in the afternoon and rose 6.75 per cent to HK $9.80 as of press time, with a turnover of HK $46.3467 million. Announcement show
Shenwei Pharmaceutical (02877) adopts New dividend Policy
Shenwei Pharmaceutical (02877) announced that it expects to declare and distribute a total dividend of 60 cents per share in the calendar year 2021 (including the final dividend of 21 cents per share for the year ended 31 December 2021 paid on 17 June 2021). In addition, the Board has approved and adopted a new dividend policy with effect from July 19, 2021. As a result, the dividend policy stated in the company's 2020 report has been abolished.
Shenwei Pharmaceutical (02877.HK) rose 10.22%.
Original title: [dynamic stock] Shenwei Pharmaceutical (02877.HK) rose 10.22% Source: Caihua net [Caihua Social News] Shenwei Pharmaceutical (02877.HK) rose 10.22% as of 14:24, and now reports HK $9.17, or HK $0.85. 4.8 million shares were traded, involving 41.9 million yuan. (source: FinetAI)
Dahua Jixian: significantly increase the target price of Shenwei Pharmaceutical (02877.HK) to HK $11.80
Original title: Dahua Jixian: significantly raised the target price of Shenwei Pharmaceutical Company (02877.HK) to HK $11.8 Source: Caihua net [Caihua Social News] Dahuaxian released a report that substantially raised the target price of Shenwei Pharmaceutical Company (02877.HK) from the original HK $8.44 to HK $11.8, an increase of 39.8% or HK $6.52; the investment rating is "Buy". The report points out that Shenwei Pharmaceutical continues to recover from the novel coronavirus epidemic this year. As China opens up the traditional Chinese medicine formula granule industry to market competition, Shenwei is ready to expand the market. Shenwei Pharmaceutical Co., Ltd.
神威药业(02877.HK)：中药配方颗粒快速增长，企业现金流充沛，维持"买入"评级，目标价8.67港元
原标题：神威药业(02877.HK)：中药配方颗粒快速增长，企业现金流充沛，维持"买入"评级，目标价8.67港元 来源：格隆汇 机构：国元证券 目标价：8.67港元 投资要点 中药注射液占比下降，口服产品贡献公司毛利达 72.3%： 公司口服类产品包括软胶囊、颗粒剂、中药配方颗粒及其他剂型，2019 年口服类产品持续发力实现 14.8 亿元营业收入，同比增速 20.8%，占总营收54.7%
Loading...
No Stock Yet